Point of Care Molecular Diagnostics Market

Point of Care Molecular Diagnostics Market by Product (Assays, Kits, Analyzers, Service), Application (Respiratory Diseases, HAIs, STDs, Cancer, Hepatitis), Technology (RT-PCR, INAAT), End User (Physician Office, Hospitals, ICUs) - Global Forecast to 2026

Report Code: MD 6292 Feb, 2022, by marketsandmarkets.com

[233 Pages Report] The global point-of-care molecular diagnostics market size is projected to reach USD 4.1 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 8.2% during the forecast period. Market growth is driven by the increasing prevalence of infectious diseases and cancer, rising focus on decentralized diagnostics, increasing R&D funding, increasing awareness on the early detection of infectious diseases, and the increasing use of POC diagnostic tests.

Point of Care Molecular Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on Global Point-of-Care Molecular Diagnostics Market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a matter of a few weeks. The COVID-19 pandemic negatively affected the overall sales of most of the companies but had an positive impact on the point-of-care molecular diagnostics market because of the use of molecular diagnostic methods for COVID-19 testing. Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents. However, a resurgence in testing numbers is seen as countries gradually ease restrictions on movement. With the COVID-19 pandemic, responding to infectious disease has become a pressing medical issue worldwide. In addition to the development of vaccines and therapeutic drugs, there is a growing call for the development of more precise and simple testing technologies and the expansion of testing structures. COVID-19 has also impacted the regulatory environment and practices, as governments and healthcare providers face unprecedented challenges. Regulatory authorities utilized methods to speed approval of diagnostic products. Companies have taken strategic developments to introduce COVID-19 rapid tests, sustain their revenues, and nullify the impact of COVID-19 on their operational capabilities

Market Dynamics

Driver: Increasing prevalence of infectious diseases and cancer

The increasing prevalence of infectious diseases and cancer in developed and developing regions will positively influence the growth of the point-of-care molecular diagnostics market. The diagnosis and management of such diseases are responsible for the increasing number of prescriptions for molecular diagnostic tests. These factors, alongside the growing trend for preventive medicine, is expected to drive the demand for point-of-care molecular diagnostics during the forecast period.

Opportunity: Growth opportunities in emerging countries

Emerging economies such as India, South Korea, Brazil, and Mexico offer significant growth opportunities to players operating in the point-of-care molecular diagnostics market. This can be attributed to the low regulatory barriers, improvements in healthcare infrastructure, growing patient population, rising prevalence of infectious diseases, and rising healthcare expenditure. Moreover, the regulatory policies in some of these countries are more adaptive and business-friendly than those in developed countries.

Restraint: Unfavourable reimbursement scenario

Inadequate reimbursements are a major factor restraining the growth of the point-of-care molecular diagnostics market. A major challenge that most diagnostic companies face in commercializing their tests is getting Medicare and private health insurers to pay for them. In the US, Medicare revised its reimbursement mechanism for some IVD tests, including point-of-care molecular tests, in 2018. Some of these tests do not have their own Healthcare Common Procedure Coding System (HCPCS) codes and are instead billed using unlisted codes. In such cases, Medicare Administrative Contractors (MACs) establish a payment amount for their local jurisdictions. Centers for Medicare & Medicaid Services (CMS) reduced the Medicare reimbursement rate for COVID-19 tests based on high throughput technology to USD 75 unless labs can process results in under two days. Medicare does not currently provide genetic testing coverage in individuals without a personal history of cancer (Source: American Society of Clinical Oncology).

In 2020, assays & kits segment accounted for the largest share of the point-of-care molecular diagnostics market, by product & service

Based on product, the point-of-care molecular diagnostics market is segmented into instruments & analyzers, and software & services. In 2020, the assays & kits segment accounted for the largest share of this market. The frequent purchase of these products due to their recurrent usage drives the market growth of this segment.

In 2020, RT-PCR segment accounted for the largest share in the market, by technology

The point-of-care molecular diagnostics market is segmented into RT-PCR, INAAT and other technologies based on technology. In 2020, the RT-PCR segment accounted for the largest share. This can be attributed to the growing use of RT-PCR in proteomics, genomics, and COVID-19 testing as well as the access to portable, easy-to-use devices are the major factors driving the growth of this market segment.

North America is the largest regional market for point-of-care molecular diagnostics

The global point-of-care molecular diagnostics market is segmented into North America, Europe, Asia Pacific and Rest of the World. In 2020, North America accounted for the largest share of the global point-of-care molecular diagnostics market. The North American point-of-care molecular diagnostics market's growth can be attributed to the highly developed healthcare system in the US and Canada and the easy accessibility to technologically advanced instruments.

Point of Care Molecular Diagnostics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Some key players in the point-of-care molecular diagnostics market (2021- 2026)

  • Abbott Laboratories (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • bioMérieux SA (France)
  • Danaher Corporation (US)
  • Quidel Corporation (US)
  • QIAGEN N.V. (Netherlands)
  • Co-Diagnostics, Inc. (US)
  • Biocartis NV (Belgium)
  • Meridian Bioscience, Inc. (US)
  • Thermo Fisher Scientific, Inc. (US)
  • Lucira Health, Inc. (US)
  • Cue Health (US)
  • OpGen, Inc. (US)
  • Binx Health, Inc. (US)
  • Molbio Diagnostics Pct. Ltd. (India)
  • Genomadix (Canada)
  • Visby Medical, Inc. (US)
  • QuikPath PTE Ltd. (Singapore)
  • MD-Bio (US)
  • QuantuMDx Group Ltd. (UK)
  • Aidian Oy (Finland)
  • GeneSTAT Molecular Diagnostics, LLC (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2018–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD)

Segments covered

Product & Service, technology, application, end user, and region

Geographies covered

North America, Europe, Asia Pacific and Rest of the World

Companies covered

Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Danaher Corporation (US), Quidel Corporation (US), QIAGEN N.V. (Netherlands), Co-Diagnostics, Inc. (US), Biocartis NV (Belgium), Meridian Bioscience, Inc. (US), Thermo Fisher Scientific, Inc. (US), Lucira Health, Inc. (US), Cue Health (US), OpGen, Inc. (US), Binx Health, Inc. (US), Molbio Diagnostics Pct. Ltd. (India), Genomadix (Canada), Visby Medical, Inc. (US), QuikPath PTE Ltd. (Singapore), MD-Bio (US), QuantuMDx Group Ltd. (UK), Aidian Oy (Finland), and GeneSTAT Molecular Diagnostics, LLC (US)

This report categorizes the point-of-care molecular diagnostics market into the following segments and subsegments:

By Product & Service

  • Assays & kits
  • Instruments & Analyzers
  • Software & Services

By Technology

  • RT-PCR
  • INAAT
  • Other technologies

By Application

  • Respiratory Diseases
  • Sexually Transmitted Diseases
  • Hospital-acquired Infections
  • Cancer
  • Hepatitis
  • Gastrointestinal Disorders
  • Other Applications

By End User

  • Physicians’ Offices
  • Hospitals & ICUs
  • Research Institutes
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Rest of Europe (RoE)
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific (RoAPAC)
  • Rest of the World (RoW)

Recent Developments

  • In October 2020, bioMérieux SA partnered with Africa Medical Supplies Platform (AMSP) to supply high-quality COVID-19 diagnostic solutions from the bioMérieux Pandemic Response Portfolio to African Union Member States.
  • In March 2020, Abbott Laboratories launched the ID NOW PoC testing system.
  • In October 2018, QIAGEN signed an agreement with STAT-Dx to add QIAstat-Dx, a next-generation PCR-based multiplex syndromic testing solution, to QIAGEN’s portfolio

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 34)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
           1.2.2 MARKETS COVERED
                    FIGURE 1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION
           1.2.3 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 38)
    2.1 RESEARCH DATA
    2.2 RESEARCH APPROACH
           FIGURE 2 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Primary sources
                    2.2.2.2 Key data from primary sources
                    2.2.2.3 Key industry insights
                    2.2.2.4 Breakdown of primary interviews
                               FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
                               FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Approach 1: Company revenue estimation approach
                               FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.3.1.2 Approach 2: Market estimation from the parent market
                               FIGURE 6 BOTTOM-UP APPROACH: MARKET ESTIMATION FROM THE PARENT MARKET
                    2.3.1.3 Approach 3: Presentations of companies and primary interviews
                    2.3.1.4 Growth forecast
                    2.3.1.5 CAGR projections
                               FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN & DATA TRIANGULATION
           FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE ANALYSIS
    2.6 ASSUMPTIONS FOR THE STUDY
    2.7 RISK ASSESSMENT
           2.7.1 RISK ASSESSMENT: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
    2.8 GROWTH RATE ASSUMPTIONS
    2.9 COVID-19 HEALTH ASSESSMENT
    2.10 COVID-19 ECONOMIC ASSESSMENT
    2.11 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
           FIGURE 10 CRITERIA IMPACTING THE GLOBAL ECONOMY
           FIGURE 11 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
    2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY (Page No. - 53)
    FIGURE 12 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
    FIGURE 13 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    FIGURE 14 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 15 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    FIGURE 16 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 58)
    4.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW
           FIGURE 17 RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD
    4.2 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
           FIGURE 18 ASSAYS & KITS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
    4.3 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
           FIGURE 19 RT-PCR SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
    4.4 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION, 2021 VS. 2026
           FIGURE 20 RESPIRATORY DISEASES SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
    4.5 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER, 2021 VS. 2026
           FIGURE 21 PHYSICIANS’ OFFICES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
    4.6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 22 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 62)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing prevalence of infectious diseases and cancer
                    5.2.1.2 Rising focus on decentralized diagnostics and increasing R&D funding
                    5.2.1.3 Increasing awareness on the early detection of infectious diseases
                    5.2.1.4 Increasing use of POC diagnostic tests
           5.2.2 RESTRAINTS
                    5.2.2.1 Unfavorable reimbursement scenario
                    5.2.2.2 High capital investments and low cost-benefit ratio
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growing R&D activities in point-of-care molecular diagnostics testing
                    5.2.3.2 Growth opportunities in emerging countries
           5.2.4 CHALLENGES
                    5.2.4.1 Stringent and time-consuming regulatory policies that significantly increase the product launch cycle
                    5.2.4.2 Introduction of alternative technologies
    5.3 IMPACT OF COVID-19 ON THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
    5.4 PRICING ANALYSIS
           TABLE 1 PRICES OF POINT-OF-CARE MOLECULAR DIAGNOSTIC PRODUCTS (2021)
    5.5 PATENT ANALYSIS
    5.6 TRADE ANALYSIS
           5.6.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
                    TABLE 2 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)
                    TABLE 3 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)
    5.7 VALUE CHAIN ANALYSIS
           FIGURE 24 MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES
    5.8 SUPPLY CHAIN ANALYSIS
           FIGURE 25 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
    5.9 ECOSYSTEM ANALYSIS
           FIGURE 26 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
           5.9.1 ROLE IN THE ECOSYSTEM
    5.10 PORTER’S FIVE FORCES ANALYSIS
           TABLE 4 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.10.1 THREAT FROM NEW ENTRANTS
           5.10.2 THREAT FROM SUBSTITUTES
           5.10.3 BARGAINING POWER OF BUYERS
           5.10.4 BARGAINING POWER OF SUPPLIERS
           5.10.5 DEGREE OF COMPETITION
    5.11 PESTLE ANALYSIS
    5.12 REGULATORY LANDSCAPE
           5.12.1 NORTH AMERICA
                    5.12.1.1 US
                    5.12.1.2 CANADA
           5.12.2 EUROPE
           5.12.3 ASIA PACIFIC
                    5.12.3.1 Japan
                    5.12.3.2 India
                    5.12.3.3 China
           5.12.4 LATIN AMERICA
                    5.12.4.1 Brazil
                    5.12.4.2 Mexico
           5.12.5 MIDDLE EAST
           5.12.6 AFRICA
    5.13 TECHNOLOGY ANALYSIS
    5.14 DISRUPTIVE TECHNOLOGIES IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
           5.14.1 REVENUE SHIFT AND REVENUE POCKETS FOR THE POC MOLECULAR DIAGNOSTICS MARKET
                     FIGURE 27 REVENUE SHIFT FOR THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET

6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 81)
    6.1 INTRODUCTION
           TABLE 5 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
           TABLE 6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
    6.2 ASSAYS & KITS
           6.2.1 RECURRENT PURCHASE OF ASSAYS & KITS IS A MAJOR FACTOR DRIVING MARKET GROWTH
                    TABLE 7 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2021–2026 (USD MILLION)
    6.3 INSTRUMENTS & ANALYZERS
           6.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE GROWTH IN THIS MARKET SEGMENT
                    TABLE 9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2021–2026 (USD MILLION)
    6.4 SOFTWARE & SERVICES
           6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE GROWTH IN THIS MARKET SEGMENT
                    TABLE 11 POINT-OF-CARE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 12 POINT-OF-CARE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2026 (USD MILLION)

7 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 87)
    7.1 INTRODUCTION
           TABLE 13 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
           TABLE 14 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
    7.2 RT-PCR
           7.2.1 GROWING USE OF RT-PCR IN COVID-19 TESTING IS A MAJOR DRIVER FOR THIS SEGMENT
                    TABLE 15 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 16 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2021–2026 (USD MILLION)
    7.3 INAAT
           7.3.1 COST BENEFITS OF INAAT ARE A KEY FACTOR DRIVING MARKET GROWTH
                    TABLE 17 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 18 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021–2026 (USD MILLION)
    7.4 OTHER TECHNOLOGIES
           TABLE 19 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2018–2020 (USD MILLION)
           TABLE 20 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2026 (USD MILLION)

8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 93)
    8.1 INTRODUCTION
           TABLE 21 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
           TABLE 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
    8.2 RESPIRATORY DISEASES
           8.2.1 GROWING PREVALENCE OF COVID-19 TO DRIVE GROWTH IN THIS MARKET SEGMENT
                    TABLE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 24 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2021–2026 (USD MILLION)
    8.3 SEXUALLY TRANSMITTED DISEASES
           8.3.1 TECHNOLOGICAL ADVANCEMENTS FOR THE DETECTION OF STDS PLAY A MAJOR ROLE IN DRIVING THE GROWTH OF THIS MARKET
                    TABLE 25 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 26 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SEXUALLY TRANSMITTED DISEASES, BY REGION, 2021–2026 (USD MILLION)
    8.4 HOSPITAL-ACQUIRED INFECTIONS
           8.4.1 RISING BURDEN OF MRSA WILL DRIVE THE GROWTH OF THE MARKET IN THE COMING YEARS
                    TABLE 27 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 28 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021–2026 (USD MILLION)
    8.5 CANCER
           8.5.1 RISING PREVALENCE OF CANCER AND GROWING FUNDING FOR CANCER RESEARCH TO DRIVE MARKET GROWTH
                    TABLE 29 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2021–2026 (USD MILLION)
    8.6 HEPATITIS
           8.6.1 INCREASE IN CASES OF HEPATITIS AMONG HIGH-RISK SUBGROUP POPULATIONS TO DRIVE MARKET GROWTH
                    TABLE 31 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2021–2026 (USD MILLION)
    8.7 GASTROINTESTINAL DISORDERS
           8.7.1 INCREASE CASES OF GASTROINTESTINAL DISORDERS TO DRIVE MARKET GROWTH
                    TABLE 33 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 34 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2026 (USD MILLION)
    8.8 OTHER APPLICATIONS
           TABLE 35 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2018–2020 (USD MILLION)
           TABLE 36 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2026 (USD MILLION)

9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (Page No. - 105)
    9.1 INTRODUCTION
           TABLE 37 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)
           TABLE 38 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
    9.2 PHYSICIANS’ OFFICES
           9.2.1 EARLY RESULTS OF POINT-OF-CARE MOLECULAR ASSAYS TO DRIVE GROWTH IN THIS MARKET
                    TABLE 39 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 40 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES, BY REGION, 2021–2026 (USD MILLION)
    9.3 HOSPITALS & ICUS
           TABLE 41 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY DISEASE TYPE, 2018–2020 (USD MILLION)
           TABLE 42 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY DISEASE TYPE, 2021–2026 (USD MILLION)
           TABLE 43 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY REGION, 2018–2020 (USD MILLION)
           TABLE 44 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY REGION, 2021–2026 (USD MILLION)
           9.3.1 SEPSIS
                    9.3.1.1 Growing need for quick diagnosis and treatment will drive growth in this market
                               TABLE 45 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS, BY REGION, 2018–2020 (USD MILLION)
                               TABLE 46 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS, BY REGION, 2021–2026 (USD MILLION)
           9.3.2 GASTROENTERITIS
                    9.3.2.1 Increasing number of gastroenteritis cases in hospital emergency departments to propel growth in this market
                               TABLE 47 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROENTERITIS, BY REGION, 2018–2020 (USD MILLION)
                               TABLE 48 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROENTERITIS, BY REGION, 2021–2026 (USD MILLION)
           9.3.3 MENINGOENCEPHALITIS
                    9.3.3.1 Severity of the disease and the need for early disease diagnosis to drive market growth
                               TABLE 49 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR MENINGOENCEPHALITIS, BY REGION, 2018–2020 (USD MILLION)
                               TABLE 50 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR MENINGOENCEPHALITIS, BY REGION, 2021–2026 (USD MILLION)
           9.3.4 OTHER DISEASES
                    TABLE 51 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 52 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2021–2026 (USD MILLION)
    9.4 RESEARCH INSTITUTES
           9.4.1 INCREASING USE OF POC MOLECULAR DIAGNOSTICS TESTS IN GENOMICS RESEARCH WILL DRIVE THIS MARKET SEGMENT
                    TABLE 53 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 54 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021–2026 (USD MILLION)
    9.5 OTHER END USERS
           TABLE 55 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2018–2020 (USD MILLION)
           TABLE 56 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2026 (USD MILLION)

10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION (Page No. - 116)
     10.1 INTRODUCTION
             TABLE 57 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2018–2020 (USD MILLION)
             TABLE 58 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021–2026 (USD MILLION)
     10.2 NORTH AMERICA
             FIGURE 28 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
             TABLE 59 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2018–2020 (USD MILLION)
             TABLE 60 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
             TABLE 61 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
             TABLE 62 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
             TABLE 63 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
             TABLE 64 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
             TABLE 65 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
             TABLE 66 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
             TABLE 67 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)
             TABLE 68 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.2.1 US
                        10.2.1.1 Increasing prevalence of infectious diseases—a key factor driving market growth in the US
                                     TABLE 69 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
                                     TABLE 70 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                     TABLE 71 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                                     TABLE 72 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                     TABLE 73 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
                                     TABLE 74 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
                                     TABLE 75 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)
                                     TABLE 76 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Rising patient population in Canada to drive market growth in the coming years
                                     TABLE 77 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
                                     TABLE 78 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                     TABLE 79 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                                     TABLE 80 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                     TABLE 81 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
                                     TABLE 82 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
                                     TABLE 83 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)
                                     TABLE 84 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
     10.3 EUROPE
             TABLE 85 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2018–2020 (USD MILLION)
             TABLE 86 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
             TABLE 87 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
             TABLE 88 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
             TABLE 89 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
             TABLE 90 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
             TABLE 91 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
             TABLE 92 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
             TABLE 93 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)
             TABLE 94 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Increasing healthcare expenditure to drive market growth in Germany
                                     TABLE 95 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
                                     TABLE 96 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                     TABLE 97 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                                     TABLE 98 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                     TABLE 99 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
                                     TABLE 100 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
                                     TABLE 101 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)
                                     TABLE 102 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.2 FRANCE
                        10.3.2.1 Rising R&D expenditure in France to drive market growth
                                     TABLE 103 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
                                     TABLE 104 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                     TABLE 105 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                                     TABLE 106 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                     TABLE 107 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
                                     TABLE 108 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
                                     TABLE 109 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)
                                     TABLE 110 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.3 ITALY
                        10.3.3.1 Adoption of advanced diagnostic technologies to drive market growth in Italy
                                     TABLE 111 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
                                     TABLE 112 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                     TABLE 113 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                                     TABLE 114 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                     TABLE 115 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
                                     TABLE 116 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
                                     TABLE 117 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)
                                     TABLE 118 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.4 UK
                        10.3.4.1 Increasing prevalence of infectious diseases to drive market growth in the UK
                                     TABLE 119 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
                                     TABLE 120 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                     TABLE 121 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                                     TABLE 122 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                     TABLE 123 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
                                     TABLE 124 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
                                     TABLE 125 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)
                                     TABLE 126 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.5 REST OF EUROPE
                        TABLE 127 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
                        TABLE 128 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                        TABLE 129 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                        TABLE 130 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                        TABLE 131 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
                        TABLE 132 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
                        TABLE 133 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)
                        TABLE 134 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
     10.4 ASIA PACIFIC
             FIGURE 29 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
             TABLE 135 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2018–2020 (USD MILLION)
             TABLE 136 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
             TABLE 137 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
             TABLE 138 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
             TABLE 139 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
             TABLE 140 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
             TABLE 141 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
             TABLE 142 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
             TABLE 143 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)
             TABLE 144 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.4.1 CHINA
                        10.4.1.1 Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth
                                     TABLE 145 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
                                     TABLE 146 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                     TABLE 147 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                                     TABLE 148 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                     TABLE 149 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
                                     TABLE 150 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
                                     TABLE 151 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)
                                     TABLE 152 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan
                                     TABLE 153 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
                                     TABLE 154 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                     TABLE 155 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                                     TABLE 156 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                     TABLE 157 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
                                     TABLE 158 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
                                     TABLE 159 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)
                                     TABLE 160 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Increasing private & public investments in the country’s healthcare system will drive market growth
                                     TABLE 161 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
                                     TABLE 162 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                     TABLE 163 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                                     TABLE 164 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                     TABLE 165 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
                                     TABLE 166 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
                                     TABLE 167 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)
                                     TABLE 168 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.4.4 REST OF ASIA PACIFIC (ROAPAC)
                        TABLE 169 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
                        TABLE 170 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                        TABLE 171 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                        TABLE 172 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                        TABLE 173 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
                        TABLE 174 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
                        TABLE 175 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)
                        TABLE 176 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
     10.5 REST OF THE WORLD
             TABLE 177 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION)
             TABLE 178 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
             TABLE 179 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
             TABLE 180 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
             TABLE 181 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION)
             TABLE 182 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
             TABLE 183 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION)
             TABLE 184 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 176)
     11.1 OVERVIEW
     11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
             11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
                        TABLE 185 STRATEGIES ADOPTED BY KEY POINT-OF-CARE MOLECULAR DIAGNOSTICS MANUFACTURING COMPANIES
     11.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
             FIGURE 30 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET (2015–2020)
     11.4 MARKET SHARE ANALYSIS
             TABLE 186 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION QUADRANT
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT, 2020
     11.6 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2020)
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                        FIGURE 33 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
     11.7 COMPETITIVE BENCHMARKING
             FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
             TABLE 187 COMPANY PRODUCT FOOTPRINT
             TABLE 188 COMPANY REGIONAL FOOTPRINT
     11.8 COMPETITIVE SCENARIO
             11.8.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 189 KEY PRODUCT LAUNCHES & APPROVALS
             11.8.2 DEALS
                        TABLE 190 KEY DEALS

12 COMPANY PROFILES (Page No. - 187)
     12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))* 
             12.1.1 ABBOTT LABORATORIES
                        TABLE 191 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
             12.1.2 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 192 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                        FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
             12.1.3 BIOMÉRIEUX SA
                        TABLE 193 BIOMÉRIEUX SA: BUSINESS OVERVIEW
                        FIGURE 37 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020)
             12.1.4 DANAHER CORPORATION
                        TABLE 194 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
             12.1.5 QUIDEL CORPORATION
                        TABLE 195 QUIDEL CORPORATION: BUSINESS OVERVIEW
                        FIGURE 39 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)
             12.1.6 QIAGEN N.V.
                        TABLE 196 QIAGEN N.V.: BUSINESS OVERVIEW
                        FIGURE 40 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
             12.1.7 CO-DIAGNOSTICS, INC.
                        TABLE 197 CO-DIAGNOSTICS, INC.: BUSINESS OVERVIEW
                        FIGURE 41 CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2020)
             12.1.8 BIOCARTIS NV
                        TABLE 198 BIOCARTIS NV: BUSINESS OVERVIEW
                        FIGURE 42 BIOCARTIS NV: COMPANY SNAPSHOT (2020)
             12.1.9 MERIDIAN BIOSCIENCE, INC.
                        TABLE 199 MERIDIAN BIOSCIENCE, INC.: BUSINESS OVERVIEW
                        FIGURE 43 MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT (2020)
             12.1.10 THERMO FISHER SCIENTIFIC INC.
                        TABLE 200 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)
     12.2 OTHER PLAYERS
             12.2.1 LUCIRA HEALTH, INC.
             12.2.2 CUE HEALTH
             12.2.3 OPGEN, INC.
             12.2.4 BINX HEALTH, INC.
             12.2.5 MOLBIO DIAGNOSTICS PVT. LTD.
             12.2.6 GENOMADIX
             12.2.7 VISBY MEDICAL, INC.
             12.2.8 QUIKPATH PTE. LTD.
             12.2.9 MD-BIO
             12.2.10 QUANTUMDX GROUP LTD.
             12.2.11 AIDIAN OY
             12.2.12 GENESTAT MOLECULAR DIAGNOSTICS, LLC
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies. 

13 APPENDIX (Page No. - 227)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the point-of-care molecular diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size.  After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.

Point of Care Molecular Diagnostics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the point-of-care molecular diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the point-of-care molecular diagnostics market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global Point-of-Care Molecular Diagnostics Market Size: Top-Down Approach

Point of Care Molecular Diagnostics Market Size, and Top-Down Approach

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, segment, and forecast the global point-of-care molecular diagnostics market by product & service, technology, application, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific and Rest of the World
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
  • To track and analyze company developments such as acquisitions, product launches and approvals, expansions, and other developments in the point-of-care molecular diagnostics market.
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

  • Point-of-Care Molecular Diagnostics market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific and Rest of the World

Company profiles

  • Additional ten company profiles of players operating in the point-of-care molecular diagnostics market
Report Code
MD 6292
Published ON
Feb, 2022
Choose License Type
BUY NOW
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Point of Care Molecular Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved